Literature DB >> 23039246

Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.

Sarka Varcabova1, Zuzana Huskova, Herbert J Kramer, Sung Hee Hwang, Bruce D Hammock, John D Imig, Kento Kitada, Ludek Cervenka.   

Abstract

The aim of the present study was to evaluate the hypothesis that the antihypertensive effects of inhibition of soluble epoxide hydrolase (sEH) are mediated by increased intrarenal availability of epoxyeicosatrienoic acids (EETs), with consequent improvement in renal haemodynamic autoregulatory efficiency and the pressure-natriuresis relationship. Ren-2 transgenic rats (TGR), a model of angiotensin (Ang) II-dependent hypertension, and normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats were treated with the sEH inhibitor cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy)benzoic acid (c-AUCB; 26 mg/L) for 48 h. Then, the effects on blood pressure (BP), autoregulation of renal blood flow (RBF) and glomerular filtration rate (GFR), and on the pressure-natriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP) were determined. Treatment with c-AUCB did not significantly change BP, renal autoregulation or pressure-natriuresis in normotensive HanSD rats. In contrast, c-AUCB treatment significantly reduced BP, increased intrarenal bioavailability of EETs and significantly suppressed AngII levels in TGR. However, treatment with c-AUCB did not significantly improve the autoregulatory efficiency of RBF and GFR in response to reductions of RAP and to restore the blunted pressure-natriuresis relationship in TGR. Together, the data indicate that the antihypertensive actions of sEH inhibition in TGR are predominantly mediated via significant suppression of intrarenal renin-angiotensin system activity.
© 2012 The Authors Clinical and Experimental Pharmacology and Physiology © 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23039246      PMCID: PMC3769696          DOI: 10.1111/1440-1681.12018

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  45 in total

1.  Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene.

Authors:  J Springate; J Van Liew; D Ganten
Journal:  Kidney Blood Press Res       Date:  1997       Impact factor: 2.687

Review 2.  Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27.

Authors:  M A Lee; M Böhm; M Paul; M Bader; U Ganten; D Ganten
Journal:  Am J Physiol       Date:  1996-06

3.  Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein.

Authors:  P L Li; W B Campbell
Journal:  Circ Res       Date:  1997-06       Impact factor: 17.367

4.  Lifelong angiotensin-converting enzyme inhibition, pressure natriuresis, and renin-angiotensin system gene expression in transgenic (mRen-2)27 rats.

Authors:  A Lippoldt; V Gross; J Bohlender; U Ganten; F C Luft
Journal:  J Am Soc Nephrol       Date:  1996-10       Impact factor: 10.121

5.  Altered pressure natriuresis in chronic angiotensin II hypertension in rats.

Authors:  J van der Mark; R L Kline
Journal:  Am J Physiol       Date:  1994-03

6.  Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats.

Authors:  R L Kline; F Liu
Journal:  Hypertension       Date:  1994-10       Impact factor: 10.190

7.  Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats.

Authors:  J Bohlender; J Ménard; O Edling; D Ganten; F C Luft
Journal:  Am J Physiol       Date:  1998-05

8.  Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.

Authors:  L Cervenka; C T Wang; L G Navar
Journal:  Am J Physiol       Date:  1998-05

9.  Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats.

Authors:  S M Jacinto; J J Mullins; K D Mitchell
Journal:  Am J Physiol       Date:  1999-02

10.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

View more
  10 in total

1.  Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis.

Authors:  Luca Vanella; Martina Canestraro; Craig R Lee; Jian Cao; Darryl C Zeldin; Michal L Schwartzman; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-04-20       Impact factor: 3.072

Review 2.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

3.  Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use.

Authors:  Jun-Yan Liu; Christophe Morisseau; Huazhang Huang; Bruce D Hammock
Journal:  J Ethnopharmacol       Date:  2016-10-01       Impact factor: 4.360

4.  Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.

Authors:  Věra Čertíková Chábová; Petr Kujal; Petra Škaroupková; Zdeňka Varňourková; Šárka Vacková; Zuzana Husková; Soňa Kikerlová; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Iwona Baranowska; Sung Hee Hwang; Bruce D Hammock; John D Imig; Vladimír Tesař; Ludek Červenka
Journal:  Kidney Blood Press Res       Date:  2018-03-06       Impact factor: 2.687

5.  Androgen-induced hypertension in angiotensinogen deficient mice: role of 20-HETE and EETS.

Authors:  Victor Garcia; Jennifer Cheng; Adam Weidenhammer; Yan Ding; Cheng-Chia Wu; Fan Zhang; Katherine Gotlinger; John R Falck; Michal L Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-12-17       Impact factor: 3.072

6.  1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats.

Authors:  I A Bukhari; B I Alorainey; A A Al-Motrefi; A Mahmoud; W B Campbell; B D Hammock
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-08       Impact factor: 3.507

7.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

8.  Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.

Authors:  Alexandra Sporková; Sárka Jíchová; Zuzana Husková; Libor Kopkan; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Herbert J Kramer; Luděk Cervenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-12       Impact factor: 2.557

9.  Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids.

Authors:  James M Luther; Dawei S Wei; Kakali Ghoshal; Dungeng Peng; Gail K Adler; Adina F Turcu; Hui Nian; Chang Yu; Carmen C Solorzano; Ambra Pozzi; Nancy J Brown
Journal:  Hypertension       Date:  2021-02-15       Impact factor: 10.190

10.  Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.

Authors:  Petr Kujal; Vera Čertíková Chábová; Petra Škaroupková; Zuzana Husková; Zdena Vernerová; Herbert J Kramer; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Kento Kitada; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Ludek Červenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-03       Impact factor: 2.557

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.